视力检测技术开发商Eyebot获得2000万美元A轮融资，用于扩展视力保健的获取途径-动脉网

Eyebot Raises $20 Million Series A Led by General Catalyst to Expand Access to Vision Care

CISION 等信源发布 2025-08-26 21:00



可切换为仅中文







New funding will support partnerships, product innovation, and team growth across the U.S.

新资金将支持美国各地的合作伙伴关系、产品创新和团队成长。

BOSTON

波士顿

，

Aug. 26, 2025

2025年8月26日

/PRNewswire/ --

Eyebot

眼球机器人

, the company behind the 90-second vision test kiosk that delivers doctor-verified glasses prescriptions, today announced it has raised

，这家位于90秒视力测试亭背后的公司，该测试亭提供经医生验证的眼镜处方，今天宣布已筹集到资金

$20 million

2000万美元

in Series A funding. The round was led by

A轮融资。此轮融资由

General Catalyst

普通催化剂

, with participation from returning investors

，现有投资者亦有参与

AlleyCorp

阿尔利公司

，

Baukunst

建筑艺术

，

Village Global

全球乡村

, and

，以及

Ubiquity Ventures

泛在风险投资

。

继续阅读

Eyebot, the company behind the 90-second vision test kiosk that delivers doctor-verified glasses prescriptions.

Eyebot，这家90秒视力测试亭背后的公司，提供经医生验证的眼镜处方。

Eyebot is redefining how people access vision care by eliminating traditional barriers like appointment delays, insurance hurdles, and inaccessibility. Its kiosks—currently in malls, universities, retail stores, and grocery chains—provide a free, 90-second vision test that can also generate a glasses prescription reviewed and verified by licensed eye doctors..

Eyebot 正在通过消除传统障碍（如预约延迟、保险难题和不可及性）重新定义人们获取视力保健的方式。其设在商场、大学、零售店和杂货连锁店的自助服务亭提供一项免费的90秒视力测试，该测试还可以生成经过持牌眼科医生审核和验证的眼镜处方。

With this new round of funding, Eyebot will expand across hundreds of new retail locations, scale its clinical and engineering teams, and deepen its engagement with eye care professionals.

通过这一轮新的融资，Eyebot 将在数百个新的零售点进行扩张，扩大其临床和工程团队，并深化与眼科护理专业人士的合作。

'Clear vision shouldn't require months of waiting, high costs, or geographic luck,' said

“清晰的视力不应该需要数月的等待、高昂的费用或地理位置的运气，”

Matthias Hofmann

马蒂亚斯·霍夫曼

, co-founder and CEO of Eyebot. 'This funding will help us accelerate our expansion, strengthen our clinical partnerships, and bring accessible vision care to millions more people.'

Eyebot联合创始人兼首席执行官表示：“这笔资金将帮助我们加速扩展，加强临床合作，并为数百万人提供可及的视力保健。”

From Pilot to National Scale

从试点到全国规模

Since its seed round last year, Eyebot has completed over 45,000 free vision tests and is on track to deliver over half a million annually.

自从去年的种子轮融资以来，Eyebot已经完成了超过45,000次免费视力测试，并有望每年提供超过五十万次。

Eyebot is focused on enhancing the in-person optical journey, demonstrating that convenient, high-quality experiences can exist anywhere. With several major launches planned alongside leading retail partners and private practices, including high-profile announcements later this year, the company is set to drive nationwide adoption..

Eyebot 专注于改善线下验光体验，证明便捷、高质量的服务可以无处不在。通过与领先的零售合作伙伴和私人诊所计划推出的多项重要产品，以及在今年晚些时候发布的备受关注的公告，该公司准备推动全国范围的采用。

A Clinically-Sound, Doctor-Led Approach

临床可靠、医生主导的方法

Make no mistake though—Eyebot isn't replacing eye doctors—it's working with them. Eyebot aims to support eye care professionals by offering doctors new ways to scale their impact, reach untapped patients, and deliver prescriptions safely through a tech-enabled platform grounded in clinical oversight..

不过，千万不要误会——Eyebot 并不是要取代眼科医生，而是与他们合作。Eyebot 旨在通过一个基于临床监督的技术平台，为眼科护理专业人员提供支持，为医生提供扩大影响力、接触未开发患者群体以及安全交付处方的新途径。

Every vision test is reviewed by a licensed doctor. Eyebot has tested more than 2,500 patients in IRB-approved studies, proving its accuracy matches traditional in-person exams. Eyebot's doctor-reviewed prescriptions have shown to have

每次视力测试都由持牌医生审查。Eyebot在经IRB批准的研究中已经测试了2500多名患者，证明其准确性与传统的面对面检查相符。Eyebot的经过医生审查的处方显示具有

higher satisfaction scores

更高的满意度评分

than the industry average.

比行业平均水平。

To continue strengthening its clinical oversight as it scales, Eyebot has formed a

为了在扩展规模的同时继续加强其临床监督，Eyebot 已经成立了一个

Clinical Advisory Board,

临床咨询委员会，

led by Eyebot Chief Medical Officer, Dr.

由Eyebot首席医疗官博士领导，

Alexander Martin

亚历山大·马丁

, that includes leaders from both optometry and ophthalmology.

，其中包括来自视光学和眼科的领导者。

Solving the Real Access Gap

解决实际访问差距

In the US alone, more than 3 million people have vision impairment, and an additional 8 million more have vision impairment from uncorrected refractive error, such as nearsightedness

仅在美国，就有超过 300 万人视力受损，另有 800 万人因未矫正的屈光不正（如近视）而导致视力受损。

1,2

。

Millions of Americans skip care due to cost, inconvenience, or lack of nearby eye doctors. Eyebot helps fill that gap by unlocking access to high quality vision screenings in locations people already frequent such as malls, pharmacies, grocery stores, and schools.

由于费用、不便或附近缺乏眼科医生，数百万美国人跳过视力检查。Eyebot 通过在人们经常光顾的地方（如商场、药店、杂货店和学校）解锁高质量视力筛查的访问权限，帮助填补了这一空白。

'Wider access to high quality eye screenings will lead to more doctor visits, which in turn will allow for earlier detection of diseases and save sight',

“更广泛地获得高质量的眼科筛查将促使更多人去看医生，这反过来将有助于更早地发现疾病并挽救视力。”

said Eyebot's Chief Medical Officer, Dr. Martin

Eyebot首席医疗官马丁博士说

。

The Eyebot kiosks also allow emerging and online eyewear retailers to open physical storefronts with a fraction of the footprint needed today—creating new models for delivering care and driving retail efficiency. At the same time, Eyebot allows established brick-and-mortar retailers to expand their capacity for vision testing by embedding Eyebot into the places people already shop..

Eyebot信息亭还使新兴和在线眼镜零售商能够以今天所需的一小部分空间开设实体店——创造新的护理交付模式并提高零售效率。同时，Eyebot使已有的实体零售商能够通过将其嵌入人们已经购物的场所来扩展视力测试的能力。

'We invested in Eyebot because they've built something simple, scalable, and incredibly impactful,' said

“我们投资Eyebot是因为他们构建了一些简单、可扩展且影响深远的东西，”

Caitlin Donovan

凯特琳·多诺万

, Partner at General Catalyst. 'They're tackling a real access challenge in healthcare and doing it in a way that supports clinicians, retailers, and consumers alike.'

，General Catalyst的合伙人。 “他们正在解决医疗保健领域的一个实际访问挑战，并且是以一种支持临床医生、零售商和消费者的方式进行的。”

About Eyebot

关于Eyebot

Eyebot is transforming how people access vision care. Its 90-second vision test helps patients get the prescriptions they need—fast, affordably, and without the need for insurance or appointments. Every test is reviewed by a licensed eye doctor to ensure accuracy and clinical oversight. With a mission to make vision care accessible to everyone, equally, at the touch of a button, Eyebot is pioneering a new future for vision care..

Eyebot 正在改变人们获取视力保健的方式。其 90 秒的视力测试帮助患者快速、经济地获得所需的处方，且无需保险或预约。每次测试均由持牌眼科医生审核，以确保准确性和临床监督。Eyebot 致力于通过一键操作让每个人平等地获得视力保健服务，开创视力保健的新未来。

About General Catalyst

关于通用催化剂

General Catalyst is a global investment and transformation company that partners with the world's most ambitious entrepreneurs to drive resilience and applied AI.

通用催化剂是一家全球投资和转型公司，与世界上最有抱负的企业家合作，推动韧性和应用人工智能。

We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond.

我们支持具有长期视野、挑战现状的创始人，与他们从种子阶段到成长阶段及以后的整个过程合作。

With offices in

在以下地点设有办公室

San Francisco

旧金山

，

New York City

纽约市

，

Boston

波士顿

，

Berlin

柏林

，

Bangalore

班加罗尔

, and

，以及

London

伦敦

, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Applied Intuition, Commure, Glean, Guild, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto.

我们已经支持了800多家企业的成长，包括Airbnb、Anduril、Applied Intuition、Commure、Glean、Guild、Gusto、Helsing、Hubspot、Kayak、Livongo、Mistral、Ramp、Samsara、Snap、Stripe、Sword和Zepto。

For more:

更多内容请访问：

www.generalcatalyst.com

, @generalcatalyst

，@generalcatalyst

Media Contact:

媒体联系人：

Gretchen Pahia

格雷琴·帕希亚

Pitch Public Relations

投稿公共关系

gretchen@pitchpublicrelations.com